Human Papilloma Virus 16 E2 (HPV-16 E2) Antikörper
Kurzübersicht für Human Papilloma Virus 16 E2 (HPV-16 E2) Antikörper (ABIN6937435)
Target
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Aufreinigung
- Purified by Protein A/G
-
Immunogen
- Raised against Vaccinia-E2 followed by intravenous injection of the maltose binding protein MBP-E2
-
Isotyp
- IgG1 kappa
-
-
-
-
Applikationshinweise
-
Positive Control: HPV-16 infected cells. Cervical tissue.
Known Application: Western Blot (1-2 μg/mL), Optimal dilution for a specific application should be determined.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Buffer
- 10 mM PBS without BSA and without Azide.
-
Konservierungsmittel
- Azide free
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months.
-
Haltbarkeit
- 24 months
-
-
- Human Papilloma Virus 16 E2 (HPV-16 E2)
-
Andere Bezeichnung
- HPV16 E2 (Human Papilloma Virus 16)
-
Substanzklasse
- Viral Protein
-
Hintergrund
- The human papilloma virus (HPV) family of DNA tumor viruses includes HPV16, a strain that is responsible for the largest number of cases of cervical cancers linked to the family. HPV16E1 and HPV16E2 are proteins that are involved in the regulation of viral DNA replication and are important for infected cell homeostasis. HPV16E2 specifically regulates the expression of the E6 and E7 oncoproteins by binding to four sites within the viral long control region, possibly involving interactions with nuclear hormone receptors. Integration of the HPV genome into the host DNA usually disrupts the HPV16E2 gene open reading frames, resulting in an overexpression of E6 and E7 genes, an event that may lead to the malignant transformation of cervical cancer. HPV16E2 is also able to induce apoptotic cell death via two pathways: the first through the binding of p53 and the second through the binding of the viral genome.
-
Molekulargewicht
- 43kDa
Target
-